3598 related articles for article (PubMed ID: 31294382)
41. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
42. Surgery in the age of biologics.
Wong DJ; Roth EM; Feuerstein JD; Poylin VY
Gastroenterol Rep (Oxf); 2019 Apr; 7(2):77-90. PubMed ID: 30976420
[TBL] [Abstract][Full Text] [Related]
43. Benefits of Biosimilars in the Management of Patients with Inflammatory Bowel Disease: An International Survey.
D'Amico F; Peyrin-Biroulet L; Danese S
J Clin Med; 2024 May; 13(11):. PubMed ID: 38892780
[No Abstract] [Full Text] [Related]
44. A national survey on the patterns of treatment of inflammatory bowel disease in Canada.
Hilsden RJ; Verhoef MJ; Best A; Pocobelli G
BMC Gastroenterol; 2003 Jun; 3():10. PubMed ID: 12791168
[TBL] [Abstract][Full Text] [Related]
45. Behavioural interventions for urinary incontinence in community-dwelling seniors: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2008; 8(3):1-52. PubMed ID: 23074508
[TBL] [Abstract][Full Text] [Related]
46. Systematic analysis of therapeutic patterns and healthcare use during 12 months before inflammatory bowel disease-related hospitalization in Switzerland.
Schoepfer A; Vavricka SR; Brüngger B; Blozik E; Bähler C
Eur J Gastroenterol Hepatol; 2020 Mar; 32(3):350-357. PubMed ID: 31834046
[TBL] [Abstract][Full Text] [Related]
47. The 2023 Impact of Inflammatory Bowel Disease in Canada: Epidemiology of IBD.
Coward S; Benchimol EI; Kuenzig ME; Windsor JW; Bernstein CN; Bitton A; Jones JL; Lee K; Murthy SK; Targownik LE; Peña-Sánchez JN; Rohatinsky N; Ghandeharian S; Im JHB; Davis T; Weinstein J; Goddard Q; Bennett J; Caplan L; Bergevin M; Yang XY; Mason K; Sanderson R; Brass C; Kaplan GG
J Can Assoc Gastroenterol; 2023 Sep; 6(Suppl 2):S9-S15. PubMed ID: 37674492
[TBL] [Abstract][Full Text] [Related]
48. Use of pharmaceuticals by inflammatory bowel disease patients: a population-based study.
Metge CJ; Blanchard JF; Peterson S; Bernstein CN
Am J Gastroenterol; 2001 Dec; 96(12):3348-55. PubMed ID: 11774948
[TBL] [Abstract][Full Text] [Related]
49. Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease.
Bressler B; Jones J; In TSH; Lan T; Iconaru C; Marshall JK
Adv Ther; 2023 Oct; 40(10):4421-4439. PubMed ID: 37507652
[TBL] [Abstract][Full Text] [Related]
50. Shifting Health Care Use from Hospitalisations and Surgeries to Outpatient Visits in Children with Inflammatory Bowel Disease: A Population-based Cohort Study from Ontario, Canada.
Dheri AK; Kuenzig ME; Mack DR; Murthy SK; Kaplan GG; Donelle J; Smith G; Benchimol EI
J Crohns Colitis; 2021 Dec; 15(12):1991-2000. PubMed ID: 34019625
[TBL] [Abstract][Full Text] [Related]
51. Biosimilars in inflammatory bowel disease.
Talathi S; Baig KRKK
J Dig Dis; 2020 Nov; 21(11):610-620. PubMed ID: 32920972
[TBL] [Abstract][Full Text] [Related]
52. The Role of Biosimilars in Inflammatory Bowel Disease.
Paramsothy S; Cleveland NK; Zmeter N; Rubin DT
Gastroenterol Hepatol (N Y); 2016 Dec; 12(12):741-751. PubMed ID: 28035201
[TBL] [Abstract][Full Text] [Related]
53. Costs of inflammatory bowel disease in Germany.
Stark R; König HH; Leidl R
Pharmacoeconomics; 2006; 24(8):797-814. PubMed ID: 16898849
[TBL] [Abstract][Full Text] [Related]
54. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
[TBL] [Abstract][Full Text] [Related]
55. Perspectives of health care use and access to care for individuals living with inflammatory bowel disease in rural Canada.
Rohatinsky N; Boyd I; Dickson A; Fowler S; Peña-Sánchez JN; Quintin CL; Risling T; Russell B; Wicks K; Wicks M
Rural Remote Health; 2021 Apr; 21(2):6358. PubMed ID: 33820422
[TBL] [Abstract][Full Text] [Related]
56. Mental Health Costs of Inflammatory Bowel Diseases.
Szigethy E; Murphy SM; Ehrlich OG; Engel-Nitz NM; Heller CA; Henrichsen K; Lawton R; Meadows P; Allen JI
Inflamm Bowel Dis; 2021 Jan; 27(1):40-48. PubMed ID: 32095835
[TBL] [Abstract][Full Text] [Related]
57. Benefits of implementing a rapid access clinic in a high-volume inflammatory bowel disease center: Access, resource utilization and outcomes.
Nene S; Gonczi L; Kurti Z; Morin I; Chavez K; Verdon C; Reinglas J; Kohen R; Bessissow T; Afif W; Wild G; Seidman E; Bitton A; Lakatos PL
World J Gastroenterol; 2020 Feb; 26(7):759-769. PubMed ID: 32116423
[TBL] [Abstract][Full Text] [Related]
58. International variation in medication prescription rates among elderly patients with inflammatory bowel disease.
Benchimol EI; Cook SF; Erichsen R; Long MD; Bernstein CN; Wong J; Carroll CF; Frøslev T; Sampson T; Kappelman MD
J Crohns Colitis; 2013 Dec; 7(11):878-89. PubMed ID: 23018106
[TBL] [Abstract][Full Text] [Related]
59. The 2023 Impact of Inflammatory Bowel Disease in Canada: The Influence of Sex and Gender on Canadians Living With Inflammatory Bowel Disease.
Targownik LE; Bollegala N; Huang VH; Windsor JW; Kuenzig ME; Benchimol EI; Kaplan GG; Murthy SK; Bitton A; Bernstein CN; Jones JL; Lee K; Peña-Sánchez JN; Rohatinsky N; Ghandeharian S; Davis T; Weinstein J; Im JHB; Jannati N; Khan R; Matthews P; Jones May T; Tabatabavakili S; Jogendran R; Hazan E; Browne M; Meka S; Vukovic S; Jogendran M; Hu M; Osei JA; Wang GY; Sheekha TA; Dahlwi G; Goddard Q; Gorospe J; Nisbett C; Gertsman S; Sousa J; Morganstein T; Stocks T; Weber A; Seow CH
J Can Assoc Gastroenterol; 2023 Sep; 6(Suppl 2):S55-S63. PubMed ID: 37674498
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
